Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Seven reasons the beleaguered biotech sector is now a ‘buy’ By: MarketWatch June 17, 2022 at 10:17 AM EDT Investors ought to take advantage of low prices for a long-term view. Read More >> Related Stocks: Alnylam Pharmaceuticals Baxter International Biogen Idec Boston Scientific Bristol-Myers Squibb Cardinal Health Gilead Sciences Johnson & Johnson Karuna Therapeutics Inc Medtronic Mirati Therapeutics Natera Inc Roche Holding AG Basel American Depositary Shares S&P Biotech SPDR Stryker Corp Turning Point Therapeutics Inc Vertex Pharmaceuticals Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Seven reasons the beleaguered biotech sector is now a ‘buy’ By: MarketWatch June 17, 2022 at 10:17 AM EDT Investors ought to take advantage of low prices for a long-term view. Read More >> Related Stocks: Alnylam Pharmaceuticals Baxter International Biogen Idec Boston Scientific Bristol-Myers Squibb Cardinal Health Gilead Sciences Johnson & Johnson Karuna Therapeutics Inc Medtronic Mirati Therapeutics Natera Inc Roche Holding AG Basel American Depositary Shares S&P Biotech SPDR Stryker Corp Turning Point Therapeutics Inc Vertex Pharmaceuticals